Navigation Links
FDA Approves Redesigned Labels for Some Merck Drugs
Date:6/10/2011

SILVER SPRING, Md., June 10, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today is announcing the approval of Merck's redesigned drug container labels that include a new standardized format to improve readability and provide better information on product and strength differentiation.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Merck's Label Standardization Project includes the revision of 34 container labels for 16 solid oral drug products regulated by the FDA's Center for Drug Evaluation and Research (CDER). Drugs affected by the revisions include: Cozaar, Crixivan, Hyzaar, Isentress, Janumet, Januvia, Mevacor, Noroxin, Prinivil, Prinizide, Propecia, Proscar, Singulair, Zocor, and Zolinza.

"We commend Merck for their efforts," said Janet Woodcock, M.D., director of CDER. "This was no small undertaking, and we are hopeful that Merck's new standardized labels will aid in reducing pharmacy selection errors."

Merck's project included evaluating the proposed label content and layout, selecting new packaging design, and obtaining regulatory approval to implement the new packaging design. The Label Standardization Project process included:

  • a scientific approach to label design through Human Factors Engineering and Usability Studies;
  • incorporation of feedback received from the FDA and from label surveys;
  • a bundled supplement regulatory approach to ensure that labels were acceptable across CDER's eight clinical divisions.

To better access the impact of these label changes, the FDA encourages health care providers to report medication errors related to the products included in Merck's Label Standardization Project to MedWatch, the FDA's adverse event reporting program.

For more information:

MedWatch, the FDA's adverse event reporting program

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
(Date:9/17/2014)... September 17, 2014 ... has shown positive data in a Phase 2a proof ... , Glenmark Pharmaceuticals today announced ... 1 (TRPA1) antagonist, GRC 17536 has shown positive data ... proof of concept study conducted on 138 patients in ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus ... new vegan and gluten-free Sugar Cane Fruit Mask. Their ... results skincare testers were looking for. , “My ... mask that provided results, and I think I accomplished ... Fruit Mask combines Willow bark (Salix Alba extract), a ...
(Date:9/17/2014)... (HealthDay News) -- Scientists have developed a blood-cleansing device, ... the way the blood infection sepsis is treated. ... said their device works outside the body like a ... toxins out of patients, blood. "Even with the ... care units at least 30 percent of the time," ...
(Date:9/17/2014)... to reduce the need for invasive biopsies in patients ... , In a new study, researchers developed a math ... kidney inflammation to interstitial fibrosis, scarring in the ... is the only existing way to reach a definitive ... model could also be used to monitor the effectiveness ...
(Date:9/17/2014)... 17, 2014 CarePoint Health became the ... 150 CarePoint Health employees participated in the Ice Bucket ... Association. The event took place on September 9, ... CarePoint Health donated $100 to the ALS Association for ... total of approximately $15,000. The Ice Bucket Challenge was ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... made good on their pledge to cut calories in their ... together through the Healthy Weight Commitment Foundation, pledged to remove ... and 1.5 trillion by 2015. They,ve actually reduced far more: ... pledge and exceeded their pledge," said lead researcher Shu Wen ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:'Biospleen' Suggests New Way to Treat Blood Infection 2Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 3Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... First Large Scale Study Finds 73% Are From ... Consumers Union,called on hospitals today to take ... (C.-diff.) infections in light of a new report,showing ... estimates had,indicated. As the rate of hospital acquired ...
... French . , Montreal, November 11, 2008 ... that,s enabled them to reproduce complex cellular environments and ... a new study published in the journal Lab on ... Hospital Research Centre, McGill University and the Montreal Neurological ...
... is playing a key role in the largest, most ... Mental Health (NIMH) of adolescents and young adults at ... study joins the resources of Emory and seven other ... precise predictors for psychosis, and a better understanding of ...
... be an independent cause of excessive daytime sleepiness ... Researchers from Sweden performed polysomnography testing on 400 ... The apnea-hypopnea index (AHI) was calculated, and women ... very often were considered habitual snorers. Habitual snoring ...
... Proton Pump Inhibitors increase risk of major cardiovascular event by more ... for patients taking Plavix(R) Study may anticipate a role for genetic testing ... ... MHS ) today presented a study at the 2008 Scientific,Sessions of the ...
Cached Medicine News:Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 2Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 3Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 4Health News:New laser method reproduces art masterworks to protein patterns 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 3Health News:Journal CHEST: Nov. highlights 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 3Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 4
... Pulse Oximeter monitors SpO2, pulse ... is designed to provide fast, ... The device rejects spontaneous motion ... operator of excess artifacts and ...
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
Halogen-free immersion oil based on ester oil....
Immersion Oil, 150 cs...
Medicine Products: